原研机构 |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 中国 (2021-06-01), |
最高研发阶段(中国)批准上市 |
特殊审评附条件批准 (中国)、孤儿药 (美国) |
分子式C22H30Cl2N4O6 |
InChIKeyZAHQPTJLOCWVPG-UHFFFAOYSA-N |
CAS号70476-82-3 |
适应症 | 国家/地区 | 公司 | 日期 |
---|---|---|---|
外周T细胞淋巴瘤 | 中国 | 2021-06-01 |
适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
---|---|---|---|---|
鼻咽癌 | 临床3期 | 中国 | 2023-02-15 | |
复发性鼻咽癌 | 临床3期 | - | 2023-02-01 | |
难治性外周T细胞淋巴瘤 | 临床3期 | 中国 | 2021-04-14 | |
复发性NK细胞淋巴瘤,无法分类 | 临床2期 | 中国 | 2018-04-02 | |
难治性NK细胞淋巴瘤,无法分类 | 临床2期 | 中国 | 2018-04-02 | |
复发性T细胞淋巴瘤 | 临床2期 | 中国 | 2018-04-02 | |
难治性T细胞淋巴瘤 | 临床2期 | 中国 | 2018-04-02 | |
皮肤T细胞淋巴瘤 | 临床1期 | 中国 | 2016-05-10 | |
结外NK-T细胞淋巴瘤 | 药物发现 | 中国 | 2018-04-02 | |
转移性乳腺癌 | 药物发现 | 中国 | 2015-06-01 |
临床1期 | 20 | 齋構觸簾憲糧壓鑰糧鹹(製窪艱鹽膚餘艱鬱夢鏇) = 20% 鏇鬱壓艱廠衊鹹糧廠糧 (鹹鹹淵壓築遞遞艱構憲 ) | - | 2025-04-01 | |||
临床1期 | 51 | (醖顧糧糧膚鑰糧築鹹網) = 壓鹹衊構網鹹蓋鑰糧遞 願鑰鑰網選製襯網餘積 (窪壓鏇觸膚觸膚選糧憲 ) 更多 | 积极 | 2024-05-24 | |||
临床2期 | 16 | (餘廠顧蓋網淵淵膚窪夢) = 鑰繭築蓋襯願醖選廠積 齋範夢製夢餘齋鏇構製 (簾窪膚襯繭醖積遞製鹹, 窪積製醖淵鹽製壓膚選 ~ 蓋衊艱餘襯鹹繭積蓋壓) 更多 | - | 2024-04-18 | |||
ASH2023 人工标引 | N/A | 急性髓性白血病 一线 | 18 | (構憲蓋淵壓鬱鑰壓窪構) = 繭範顧壓憲製積鹽製糧 齋鏇選壓繭鹽積鹽糧構 (鹽觸膚壓憲網壓簾襯範 ) 更多 | 积极 | 2023-12-10 | |
N/A | 82 | (鹽遞顧艱夢鹽獵膚繭憲) = 73.2% 壓製築窪窪鑰簾憲顧餘 (構網鏇糧夢壓鬱獵獵膚 ) 更多 | 积极 | 2023-05-31 | |||
N/A | 晚期肉瘤 一线 | 58 | 獵衊餘糧積願襯構築醖(範獵選觸獵範觸夢選餘) = 15% of those had some evidence of cardiotoxicity, with an ejection fraction of < 50% or 10% decrease from baseline. Of the participants with changes in ejection fraction, 67% had received prior anthracycline therapy and 33% had received a total lifetime dose of doxorubicin exceeding the recommended 500 mg/m² limit 製積遞製淵淵醖淵齋壓 (鏇鏇壓製艱憲壓願醖構 ) 更多 | 不佳 | 2023-05-31 | ||
N/A | 20 | (窪範選艱蓋製襯鏇願願) = 糧鬱築鏇製淵範淵獵餘 夢獵糧鹽蓋膚憲繭艱憲 (築繭糧壓糧製廠衊醖憲 ) 更多 | - | 2023-04-23 | |||
临床3期 | 200 | (CPI-613 + HD Cytarabine and Mitoxantrone) | (鑰鹹製醖顧艱網範遞醖) = 範淵醖鏇淵網憲衊網簾 顧構淵淵顧範膚夢憲簾 (範糧窪顧鑰鑰構築膚壓, 繭鏇餘壓遞壓醖齋窪衊 ~ 製膚鏇觸顧憲願網憲網) 更多 | - | 2022-12-13 | ||
(Control (HAM) and Control Sub-groups (MEC and FLAG)) | (鑰鹹製醖顧艱網範遞醖) = 膚網夢獵觸鏇夢獵餘觸 顧構淵淵顧範膚夢憲簾 (範糧窪顧鑰鑰構築膚壓, 艱夢選積窪衊選觸積鹽 ~ 獵糧夢繭鑰衊廠齋廠齋) 更多 | ||||||
临床1期 | 铂耐药性卵巢癌 末线 | 47 | (繭鹽願顧製製艱築憲範) = The most common ≥ grade 3 TRAEs (incidence ≥10%) were leucopenia (51.1%), neutropenia (40.4%), anemia (19.1%), lymphocytopenia (17.0%) and thrombocytopenia (17.0%) 齋憲衊積鬱鹹觸積構簾 (鬱觸築鬱淵獵餘積衊窪 ) | 积极 | 2022-06-02 | ||
(platinum-resistant patients with ≥3 prior lines) | |||||||
ASCO2022 人工标引 | 临床1期 | 42 | (艱艱願獵獵鹹蓋製糧衊) = 鏇願衊醖憲鑰窪鹹獵襯 構鏇構鬱壓鹹廠夢憲網 (鹽鏇餘淵遞鹹願鏇獵壓, 37.4 ~ 74.5) 更多 | 积极 | 2022-06-02 | ||
(patients who had at least 6 months of follow up) | (艱艱願獵獵鹹蓋製糧衊) = 獵醖蓋膚艱願壓壓鑰遞 構鏇構鬱壓鹹廠夢憲網 (鹽鏇餘淵遞鹹願鏇獵壓, 40.8 ~ 84.6) 更多 |